Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer

被引：8

作者：

Cunningham, Niamh C. ^{[1
]}

Turner, Nicholas C. ^{[1
,2
,3
]}

机构：

[1] Royal Marsden Hosp, Breast Unit, London, England

[2] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

[3] Inst Canc Res, Breast Canc Now Res Ctr, London, England

来源：

CANCER CELL | 2021年 / 39卷 / 03期

关键词：

ENDOCRINE THERAPY;

D O I：

10.1016/j.ccell.2021.02.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CDK4/6 inhibitors have transformed the treatment of metastatic estrogen-receptor-positive HER2-negative breast cancer, with efficacy found consistently for three different inhibitors. Recent adjuvant trials of CDK4/6 inhibitors in early stage breast cancer have produced discordant results, shedding light on their clinical utility and future trial design.

引用

页码：307 / 309

页数：3

共 50 条

[1] Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Elisa Agostinetto
Luca Arecco
Evandro de Azambuja
[J]. Oncology and Therapy, 2024, 12 : 19 - 29
[2] Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Agostinetto, Elisa
Arecco, Luca
de Azambuja, Evandro
[J]. ONCOLOGY AND THERAPY, 2024, 12 (01) : 19 - 29
[3] The role of CDK4/6 inhibitors in early breast cancer
Gil-Gil, Miguel
Alba, Emilio
Gavila, Joaquin
de la Haba-Rodriguez, Juan
Ciruelos, Eva
Tolosa, Pablo
Candini, Daniele
Llombart-Cussac, Antonio
[J]. BREAST, 2021, 58 : 160 - 169
[4] CDK4/6 inhibitors in breast cancer
Dukelow, Tim
Kishan, Divya
Khasraw, Mustafa
Murphy, Conleth G.
[J]. ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
[5] Practice changing: CDK4/6 inhibitors in the adjuvant treatment of breast cancer
Banys-Paluchowski, M.
Paluchowski, Peter
Krawczyk, Natalia
[J]. ONKOLOGE, 2020, 26 (12): : 1167 - 1171
[6] Position paper on CDK4/6 inhibitors in early breast cancer
Michael Gnant
Christian F. Singer
Gabriel Rinnerthaler
Georg Pfeiler
Daniel Egle
Marija Balic
Rupert Bartsch
[J]. memo - Magazine of European Medical Oncology, 2023, 16 : 135 - 144
[7] Position paper on CDK4/6 inhibitors in early breast cancer
Gnant, Michael
Singer, Christian F.
Rinnerthaler, Gabriel
Pfeiler, Georg
Egle, Daniel
Balic, Marija
Bartsch, Rupert
[J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (02) : 135 - 144
[8] CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Haslam, Alyson
Ranganathan, Sruthi
Prasad, Vinay
Olivier, Timothee
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 207
[9] The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, Conleth G.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
[10] Update on CDK4/6 Inhibitors in Breast Cancer
Tolaney, Sara M.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06) : 298 - 300

← 1 2 3 4 5 →